-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $19

Benzinga·09/04/2026 17:57:44
语音播报
Goldman Sachs analyst Salveen Richter maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $28 to $19.